{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:58:49Z","timestamp":1789095529948,"version":"build-2803163510"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-024-02366-7","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T06:19:23Z","timestamp":1713421163000},"page":"2157-2176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Familial states of primary hyperparathyroidism: an update"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-9547","authenticated-orcid":false,"given":"F.","family":"Cetani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dinoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pierotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"issue":"5","key":"2366_CR1","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1210\/endrev\/bnad009","volume":"44","author":"S Jha","year":"2023","unstructured":"Jha S, Simonds WF (2023) Molecular and clinical spectrum of primary hyperparathyroidism. Endocr Rev 44(5):779\u2013818","journal-title":"Endocr Rev"},{"key":"2366_CR2","volume":"30","author":"R Halperin","year":"2022","unstructured":"Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M, Telerman A et al (2022) Germline CDKN1B variant type and site are associated with phenotype in MEN4. Endocr Relat Cancer 30:e220174","journal-title":"Endocr Relat Cancer"},{"key":"2366_CR3","doi-asserted-by":"crossref","unstructured":"Chevalier B, Coppin L, Romanet P, Cuny T, Ma\u00efza JC, Abeillon J et al (2024) Beyond MEN1, when to think about MEN4? Retrospective study on 5600 patients in the French population and literature review. J Clin Endocrinol Metab 1\u201312","DOI":"10.1210\/clinem\/dgae055"},{"issue":"4","key":"2366_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1210\/clinem\/dgaa957","volume":"106","author":"AJ Seabrook","year":"2021","unstructured":"Seabrook AJ, Harris JE, Velosa SB, Kim E, McInerney-Leo AM, Dwight T et al (2021) Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5? J Clin Endocrinol Metab 106(4):1163\u20131182","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2366_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jbmr.3650","volume":"34","author":"SJ Marx","year":"2019","unstructured":"Marx SJ, Goltzman D (2019) Evolution of our understanding of the hyperparathyroid syndromes: a historical perspective. J Bone Min Res 34(1):22\u201337","journal-title":"J Bone Min Res"},{"issue":"26","key":"2366_CR6","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1056\/NEJMoa1300253","volume":"368","author":"MA Nesbit","year":"2013","unstructured":"Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T et al (2013) Mutations affecting G-protein subunit \u03b1 11 in hypercalcemia and hypocalcemia. N Engl J Med 368(26):2476\u20132486","journal-title":"N Engl J Med"},{"issue":"1","key":"2366_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ng.2492","volume":"45","author":"MA Nesbit","year":"2013","unstructured":"Nesbit MA, Hannan FM, Howles SA, Reed AAC, Cranston T, Thakker CE et al (2013) Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat Genet 45(1):93\u201397","journal-title":"Nat Genet"},{"issue":"3","key":"2366_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/0002-9343(54)90353-8","volume":"16","author":"P Wermer","year":"1954","unstructured":"Wermer P (1954) Genetic aspects of adenomatosis of endocrine glands. Am J Med 16(3):363\u2013371","journal-title":"Am J Med"},{"key":"2366_CR9","doi-asserted-by":"crossref","unstructured":"Thakker R V, Newey PJ, Walls G V, Bilezikian J, Dralle H, Ebeling PR et al (2012) Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 97(9):2990\u20133011. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22723327","DOI":"10.1210\/jc.2012-1230"},{"issue":"4","key":"2366_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/j.1365-2265.2007.02934.x","volume":"67","author":"A Machens","year":"2007","unstructured":"Machens A, Schaaf L, Karges W, Frank-Raue K, Bartsch DK, Rothmund M et al (2007) Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) 67(4):613\u2013622","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2366_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2019.00339","volume":"10","author":"CDC Kamilaris","year":"2019","unstructured":"Kamilaris CDC, Stratakis CA (2019) Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Front Endocrinol (Lausanne) 10:1\u201315","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2366_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/qjmed\/89.9.653","volume":"89","author":"D Trump","year":"1996","unstructured":"Trump D, Farren B, Wooding C, Pang J, Besser G, Buchanan K et al (1996) Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Q J Med 89:653\u2013669","journal-title":"Q J Med"},{"key":"2366_CR13","doi-asserted-by":"crossref","unstructured":"Twigt BA, Scholten A, Valk GD, Rinkes IHMB, Vriens MR (2013) Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up. Orphanet J Rare Dis 8(1):50. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3623824&tool=pmcentrez&rendertype=abstract","DOI":"10.1186\/1750-1172-8-50"},{"issue":"8","key":"2366_CR14","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1359\/jbmr.090304","volume":"24","author":"C Eller-Vainicher","year":"2009","unstructured":"Eller-Vainicher C, Chiodini I, Battista C, Viti R, Mascia ML, Massironi S et al (2009) Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res 24(8):1404\u20131410","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2366_CR15","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1210\/jc.2014-3659","volume":"100","author":"P Goudet","year":"2015","unstructured":"Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, L\u00e9vy-Bohbot N et al (2015) MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d\u2019\u00e9tude des Tumeurs Endocrines. J Clin Endocrinol Metab 100(4):1568\u20131577","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2366_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm11071967","volume":"11","author":"MP Yavropoulou","year":"2022","unstructured":"Yavropoulou MP, Vlachou S, Tsoli M, Fostira F, Kaltsas G, Kassi E (2022) Management and long-term follow-up of hyperparathyroidism in multiple endocrine neoplasia type 1: single center experience. J Clin Med 11(7):1\u201311","journal-title":"J Clin Med"},{"issue":"1\u20132","key":"2366_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2013.08.002","volume":"386","author":"RV Thakker","year":"2014","unstructured":"Thakker RV (2014) Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 386(1\u20132):2\u201315. https:\/\/doi.org\/10.1016\/j.mce.2013.08.002","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"2366_CR18","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/SLA.0b013e31811f4467","volume":"246","author":"F Tonelli","year":"2007","unstructured":"Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML (2007) Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg 246(6):1075\u20131082","journal-title":"Ann Surg"},{"issue":"12","key":"2366_CR19","first-page":"2568","volume":"37","author":"JP Bilezikian","year":"2022","unstructured":"Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S et al (2022) Evaluation and management of primary hyperparathyroidism\u202f: summary statement and guidelines from the fifth international workshop. J Bone Miner Res 37(12):2568\u20132585","journal-title":"J Bone Miner Res"},{"key":"2366_CR20","doi-asserted-by":"crossref","unstructured":"De Menezes Montenegro FL, Brescia MDEG, Louren\u00e7o DM, Arap SS, D\u2019Alessandro AF, De Britto E Silva Filho G et al (2019) Could the less-than subtotal parathyroidectomy be an option for treating young patients with multiple endocrine neoplasia type 1-related hyperparathyroidism? Front Endocrinol (Lausanne) 10:1\u201310","DOI":"10.3389\/fendo.2019.00123"},{"issue":"1","key":"2366_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56847-4","volume":"10","author":"HR Choi","year":"2020","unstructured":"Choi HR, Choi SH, Choi SM, Kim JK, Lee CR, Kang SW et al (2020) Benefit of diverse surgical approach on short-term outcomes of MEN1-related hyperparathyroidism. Sci Rep 10(1):1\u20137","journal-title":"Sci Rep"},{"issue":"2","key":"2366_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1210\/endrev\/bnaa031","volume":"42","author":"M Brandi","year":"2021","unstructured":"Brandi M, Agarwal S, Perrier N, Lines K, Valk G, Thakker R (2021) Multiple endocrine neoplasia type 1: latest insights. Endocr Rev 42(2):133\u2013170","journal-title":"Endocr Rev"},{"issue":"6","key":"2366_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S0016-5107(92)70571-9","volume":"38","author":"HD Mai","year":"1992","unstructured":"Mai HD, Sanowski RA (1992) Regression of duodenal gastrinomas in a patient with multiple endocrine neoplasia type I after parathyroidectomy. Gastrointest Endosc 38(6):706\u2013708","journal-title":"Gastrointest Endosc"},{"issue":"2","key":"2366_CR24","first-page":"302","volume":"169","author":"C Nastos","year":"2021","unstructured":"Nastos C, Papaconstantinou D, Kofopoulos-Lymperis E, Peppa M, Pikoulis A, Lykoudis P et al (2021) Optimal extent of initial parathyroid resection in patients with multiple endocrine neoplasia syndrome type 1: a meta-analysis. Surg (United States) 169(2):302\u2013310","journal-title":"Surg (United States)"},{"issue":"11","key":"2366_CR25","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1007\/s00268-022-06633-7","volume":"46","author":"D Bouriez","year":"2022","unstructured":"Bouriez D, Gronnier C, Haissaguerre M, Tabarin A, Najah H (2022) Less than subtotal parathyroidectomy for multiple endocrine neoplasia type 1 primary hyperparathyroidism: a systematic review and meta-analysis. World J Surg 46(11):2666\u20132675","journal-title":"World J Surg"},{"issue":"8","key":"2366_CR26","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00423-015-1342-7","volume":"400","author":"M Iacobone","year":"2015","unstructured":"Iacobone M, Carnaille B, Palazzo FF, Vriens M (2015) Hereditary hyperparathyroidism\u2014a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbeck\u2019s Arch Surg 400(8):867\u2013886","journal-title":"Langenbeck\u2019s Arch Surg"},{"issue":"1","key":"2366_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ando.2023.09.003","volume":"85","author":"P Goudet","year":"2024","unstructured":"Goudet P, Cadiot G, Barlier A, Baudin E, Borson-Chazot F, Brunaud L et al (2024) French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d\u2019\u00e9tude des Tumeurs Endocrines\/Association Francophonede Chirurgie Endocrinienne\/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1. Ann Endocrinol (Paris) 85(1):2\u201319","journal-title":"Ann Endocrinol (Paris)"},{"issue":"12","key":"2366_CR28","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1007\/s00268-016-3624-9","volume":"40","author":"WP Kluijfhout","year":"2016","unstructured":"Kluijfhout WP, Beninato T, Drake FT, Vriens MR, Gosnell J, Shen WT et al (2016) Unilateral clearance for primary hyperparathyroidism in selected patients with multiple endocrine neoplasia type 1. World J Surg 40(12):2964\u20132969","journal-title":"World J Surg"},{"key":"2366_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1155\/2010\/906163","volume":"2010","author":"VJ Moyes","year":"2010","unstructured":"Moyes VJ, Monson JP, Chew SL, Akker SA (2010) Clinical use of cinacalcet in MEN1 hyperparathyroidism. Int J Endocrinol 2010:10\u201313","journal-title":"Int J Endocrinol"},{"issue":"10","key":"2366_CR30","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1210\/jc.2014-1414","volume":"99","author":"R Eastell","year":"2014","unstructured":"Eastell R, Brandi ML, Costa AG, D\u2019Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab 99(10):3570\u20133579","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2366_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12020-015-0696-5","volume":"52","author":"F Giusti","year":"2016","unstructured":"Giusti F, Cianferotti L, Gronchi G, Cioppi F, Masi L, Faggiano A et al (2016) Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to multiple endocrine neoplasia syndrome type 1 (MEN1). Endocrine 52(3):495\u2013506","journal-title":"Endocrine"},{"issue":"11","key":"2366_CR32","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s40618-018-0879-z","volume":"41","author":"F Saponaro","year":"2018","unstructured":"Saponaro F, Cetani F, Repaci A, Pagotto U, Cipriani C, Pepe J et al (2018) Clinical presentation and management of patients with primary hyperparathyroidism in Italy. J Endocrinol Invest 41(11):1339\u20131348. https:\/\/doi.org\/10.1007\/s40618-018-0879-z","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2366_CR33","first-page":"655","volume":"35","author":"F Cetani","year":"2012","unstructured":"Cetani F, Saponaro F, Banti C, Cianferotti L, Vignali E, Chiavistelli S et al (2012) Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. J Endocrinol Invest 35(7):655\u2013660","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2366_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1530\/EJE-12-0117","volume":"167","author":"M Filopanti","year":"2012","unstructured":"Filopanti M, Verga U, Ermetici F, Olgiati L, Eller-Vainicher C, Corbetta S et al (2012) MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly. Eur J Endocrinol 167(2):157\u2013164","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2366_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/cen.13264","volume":"86","author":"D Donegan","year":"2017","unstructured":"Donegan D, Singh Ospina N, Rodriguez-Gutierrez R, Al-Hilli Z, Thompson GB, Clarke BL et al (2017) Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. Clin Endocrinol (Oxf) 86(2):199\u2013206","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2366_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.gie.2014.09.037","volume":"81","author":"SJ Van Asselt","year":"2015","unstructured":"Van Asselt SJ, Brouwers AH, Van Dullemen HM, Van Der Jagt EJ, Bongaerts AHH, Kema IP et al (2015) EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointest Endosc 81(1):159-167.e2. https:\/\/doi.org\/10.1016\/j.gie.2014.09.037","journal-title":"Gastrointest Endosc"},{"issue":"3","key":"2366_CR37","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.dld.2011.09.014","volume":"44","author":"C Barbe","year":"2012","unstructured":"Barbe C, Murat A, Dupas B, Ruszniewski P, Tabarin A, Vullierme MP et al (2012) Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis 44(3):228\u2013234. https:\/\/doi.org\/10.1016\/j.dld.2011.09.014","journal-title":"Dig Liver Dis"},{"issue":"5","key":"2366_CR38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/01.pas.0000194044.01104.25","volume":"30","author":"M Anlauf","year":"2006","unstructured":"Anlauf M, Schlenger R, Perren A, Bauersfeld J, Koch CA, Dralle H et al (2006) Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 30(5):560\u2013574","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2366_CR39","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1159\/000511791","volume":"111","author":"B Niederle","year":"2021","unstructured":"Niederle B, Selberherr A, Bartsch DK, Brandi ML, Doherty GM, Falconi M et al (2021) Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome\u2014an International Consensus Statement. Neuroendocrinology 111(7):609\u2013630","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2366_CR40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1572-0241.2006.00367.x","volume":"101","author":"L Thomas-Marques","year":"2006","unstructured":"Thomas-Marques L, Murat A, Delemer B, Penfornis A, Cardot-Bauters C, Baudin E et al (2006) Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 101(2):266\u2013273","journal-title":"Am J Gastroenterol"},{"key":"2366_CR41","doi-asserted-by":"crossref","unstructured":"Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P et al (2010) Risk factors and causes of death in men1 disease. A GTE (Groupe d\u2019etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34(2):249\u2013255","DOI":"10.1007\/s00268-009-0290-1"},{"issue":"7","key":"2366_CR42","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s40618-022-01985-2","volume":"46","author":"X Liu","year":"2023","unstructured":"Liu X, Chen B, Chen J, Su Z, Sun S (2023) The incidence, prevalence, and survival analysis of pancreatic neuroendocrine tumors in the United States. J Endocrinol Invest 46(7):1373\u20131384","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2366_CR43","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","volume":"86","author":"ML Brandi","year":"2001","unstructured":"Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C et al (2001) Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12):5658\u20135671","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2366_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.11138\/ccmbm\/2017.14.1.123","volume":"14","author":"F Cioppi","year":"2017","unstructured":"Cioppi F, Cianferotti L, Masi L, Giusti F, Brandi M (2017) The LARO-MEN1 study: a longitudinal clinical experience with octreotide long-acting release in patients with multiple endocrine neoplasia type 1 syndrome. Clin Cases Miner Bone Metab 14(2):123\u2013130","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"6","key":"2366_CR45","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/cen.12411","volume":"80","author":"V Ramundo","year":"2014","unstructured":"Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V et al (2014) Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf) 80(6):850\u2013855","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2366_CR46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1210\/clinem\/dgz007","volume":"105","author":"A Faggiano","year":"2020","unstructured":"Faggiano A, Modica R, Lo Calzo F, Camera L, Napolitano V, Altieri B et al (2020) Lanreotide therapy vs active surveillance in MEN1-related pancreatic neuroendocrine tumors < 2 centimeters. J Clin Endocrinol Metab 105(1):78\u201384","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2366_CR47","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nrendo.2018.3","volume":"14","author":"M Frost","year":"2019","unstructured":"Frost M, Lines KE, Thakker RV (2019) Europe PMC Funders Group current and emerging therapies for pancreatic neuroendocrine tumours in patients with or without multiple endocrine neoplasia type 1. Nat Rev Endocrinol 14(4):216\u2013227","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2366_CR48","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3171\/2020.1.JNS193538","volume":"134","author":"S Cohen-Cohen","year":"2020","unstructured":"Cohen-Cohen S, Brown DA, Himes BT, Wheeler LP, Ruff MW, Major BT et al (2020) Pituitary adenomas in the setting of multiple endocrine neoplasia type 1: a single-institution experience. J Neurosurg 134(4):1132\u20131138","journal-title":"J Neurosurg"},{"issue":"9","key":"2366_CR49","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1210\/jc.2014-1560","volume":"99","author":"JM De Laat","year":"2014","unstructured":"De Laat JM, Pieterman CR, Van Den Broek MF, Twisk JW, Hermus AR, Dekkers OM et al (2014) Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients. J Clin Endocrinol Metab 99(9):3325\u20133333","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2366_CR50","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/archderm.1997.03890430067009","volume":"133","author":"TN Darling","year":"1997","unstructured":"Darling TN, Skarulis MC, Seth M, Spiegel AM, Turner M, Marx SJ (1997) Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 133(7):853\u2013857","journal-title":"Arch Dermatol"},{"issue":"7","key":"2366_CR51","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/j.1468-3083.2008.02578.x","volume":"22","author":"A Vidal","year":"2008","unstructured":"Vidal A, Iglesias MJ, Fern\u00e1ndez B, Fonseca E, Cordido F (2008) Cutaneous lesions associated to multiple endocrine neoplasia syndrome type 1. J Eur Acad Dermatol Venereol 22(7):835\u2013838","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"2366_CR52","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.1210\/jc.2004-0218","volume":"89","author":"B Asgharian","year":"2004","unstructured":"Asgharian B, Turner ML, Gibril F, Entsuah LK, Serrano J, Jensen RT (2004) Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 89(11):5328\u20135336","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2366_CR53","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1507\/endocrj.47.569","volume":"47","author":"A Sakurai","year":"2000","unstructured":"Sakurai A, Matsumoto K, Ikeo Y, Nishio SI, Kakizawa T, Arakura F et al (2000) Frequency of facial angiofibromas in Japanese patients with multiple endocrine neoplasia type 1. Endocr J 47(5):569\u2013573","journal-title":"Endocr J"},{"issue":"July","key":"2366_CR54","first-page":"1","volume":"14","author":"L Pierotti","year":"2023","unstructured":"Pierotti L, Pardi E, Dinoi E, Piaggi P, Borsari S, Della Valentina S et al (2023) Cutaneous lesions and other non-endocrine manifestations of multiple endocrine neoplasia type 1 syndrome. Front Endocrinol (Lausanne) 14(July):1\u201313","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2366_CR55","doi-asserted-by":"crossref","unstructured":"Dreijerink KM, Goudet P, Burgess J, Valk G, Group IBC in MS (2014) Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med 371(6):583\u2013584","DOI":"10.1056\/NEJMc1406028"},{"issue":"4","key":"2366_CR56","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41574-021-00468-3","volume":"17","author":"A Al-Salameh","year":"2021","unstructured":"Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P (2021) Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol 17(4):207\u2013224","journal-title":"Nat Rev Endocrinol"},{"key":"2366_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02288-w","author":"YX Zhao","year":"2023","unstructured":"Zhao YX, Wang O, Song A, Wang LJ, Gong FY, Duan L et al (2023) The risk of concurrent malignancies in patients with multiple endocrine neoplasia type 1: insights into clinical characteristics of those with multiple endocrine neoplasia type 1. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-023-02288-w","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2366_CR58","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/hmg\/6.7.1169","volume":"6","author":"SK Agarwal","year":"1997","unstructured":"Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC et al (1997) Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 6(7):1169\u20131175","journal-title":"Hum Mol Genet"},{"key":"2366_CR59","doi-asserted-by":"crossref","unstructured":"Chandrasekharappa SC, Guru SC, Manickam P, Emmanuel OS, Emmet-t-Buck FS, Collins M et al (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (80- ) 276:404\u2013407","DOI":"10.1126\/science.276.5311.404"},{"key":"2366_CR60","doi-asserted-by":"crossref","unstructured":"Pardi E, Borsari S, Saponaro F, Bogazzi F, Urbani C, Mariotti S et al (2017) Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features. PLoS One 12(10)","DOI":"10.1371\/journal.pone.0186485"},{"issue":"1\u20132","key":"2366_CR61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.mce.2010.04.011","volume":"326","author":"K Balogh","year":"2010","unstructured":"Balogh K, Pat\u00f3cs A, Hunyady L, R\u00e1cz K (2010) Menin dynamics and functional insight: take your partners. Mol Cell Endocrinol 326(1\u20132):80\u201384","journal-title":"Mol Cell Endocrinol"},{"key":"2366_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-1-4419-1664-8_4","volume":"668","author":"GN Hendy","year":"2009","unstructured":"Hendy GN, Kaji H, Canaff L (2009) Cellular functions of menin. Adv Exp Med Biol 668:37\u201350","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"2366_CR63","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1593\/neo.06706","volume":"9","author":"SK Agarwal","year":"2007","unstructured":"Agarwal SK, Impey S, McWeeney S, Scacheri PC, Collins FS, Goodman RH et al (2007) Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation. Neoplasia 9(2):101\u2013107","journal-title":"Neoplasia"},{"issue":"4","key":"2366_CR64","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1056\/NEJM198907273210403","volume":"321","author":"RV Thakker","year":"1989","unstructured":"Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM, Spurr NK et al (1989) Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med 321(4):218\u2013224","journal-title":"N Engl J Med"},{"issue":"November","key":"2366_CR65","first-page":"1","volume":"11","author":"C Mele","year":"2020","unstructured":"Mele C, Mencarelli M, Caputo M, Mai S, Pagano L, Aimaretti G et al (2020) Phenotypes associated with MEN1 syndrome: a focus on genotype-phenotype correlations. Front Endocrinol (Lausanne) 11(November):1\u201316","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Supplement","key":"2366_CR66","doi-asserted-by":"publisher","first-page":"49","DOI":"10.6061\/clinics\/2012(Sup01)10","volume":"67","author":"CJ Lips","year":"2012","unstructured":"Lips CJ, Dreijerink KM, H\u00f6ppener JW (2012) Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation. Clinics 67(Supplement):49\u201356","journal-title":"Clinics"},{"issue":"1","key":"2366_CR67","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/humu.21170","volume":"31","author":"JJO Turner","year":"2010","unstructured":"Turner JJO, Christie PT, Pearce SHS, Turnpenny PD, Thakker RV (2010) Diagnostic challenges due to phenocopies: lessons from multiple endocrine neoplasia type1 (MEN1). Hum Mutat 31(1):1089\u20131101","journal-title":"Hum Mutat"},{"issue":"5","key":"2366_CR68","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1210\/jc.2008-2083","volume":"94","author":"SK Agarwal","year":"2009","unstructured":"Agarwal SK, Mateo CM, Marx SJ (2009) Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 94(5):1826\u20131834","journal-title":"J Clin Endocrinol Metab"},{"issue":"42","key":"2366_CR69","doi-asserted-by":"publisher","first-page":"15558","DOI":"10.1073\/pnas.0603877103","volume":"103","author":"NS Pellegata","year":"2006","unstructured":"Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, H\u00f6fler H et al (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci U S A 103(42):15558\u201315563","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2366_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2796.2009.02108.x","volume":"266","author":"M Alevizaki","year":"2009","unstructured":"Alevizaki M, Stratakis CA (2009) Multiple endocrine neoplasias: advances and challenges for the future. J Intern Med 266(1):1\u20134","journal-title":"J Intern Med"},{"issue":"2","key":"2366_CR71","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1530\/ERC-17-0456","volume":"25","author":"S Molatore","year":"2018","unstructured":"Molatore S, K\u00fcgler A, Irmler M, Wiedemann T, Neff F, Feuchtinger A et al (2018) Characterization of neuroendocrine tumors in heterozygous mutant MENX rats: a novel model of invasive medullary thyroid carcinoma. Endocr Relat Cancer 25(2):145\u2013162","journal-title":"Endocr Relat Cancer"},{"issue":"6707","key":"2366_CR72","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/24179","volume":"396","author":"ML Fero","year":"1998","unstructured":"Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ (1998) The murine gene p27 Kip1 is haplo-insufficient for tumour suppression. Nature 396(6707):177\u2013180","journal-title":"Nature"},{"issue":"4","key":"2366_CR73","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/1878-0261.12881","volume":"15","author":"D Bencivenga","year":"2021","unstructured":"Bencivenga D, Stampone E, Aulitto A, Tramontano A, Barone C, Negri A et al (2021) A cancer-associated CDKN1B mutation induces p27 phosphorylation on a novel residue: a new mechanism for tumor suppressor loss-of-function. Mol Oncol 15(4):915\u2013941","journal-title":"Mol Oncol"},{"issue":"2","key":"2366_CR74","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0411","volume":"12","author":"H Singeisen","year":"2022","unstructured":"Singeisen H, Melanie Renzulli M, Pavlicek V, Probst P, Hauswirth F, Muller MK et al (2022) Multiple endocrine neoplasia type 4: a new member of the MEN family. Endocr Connect 12(2):e220411","journal-title":"Endocr Connect"},{"issue":"4","key":"2366_CR75","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40618-022-01948-7","volume":"46","author":"I Mazarico-Altisent","year":"2023","unstructured":"Mazarico-Altisent I, Capel I, Baena N, Bella-Cueto MR, Barcons S, Guirao X et al (2023) Novel germline variants of CDKN1B and CDKN2C identified during screening for familial primary hyperparathyroidism. J Endocrinol Invest 46(4):829\u2013840","journal-title":"J Endocrinol Invest"},{"issue":"5\u20136","key":"2366_CR76","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s12672-020-00394-2","volume":"11","author":"S Khairi","year":"2020","unstructured":"Khairi S, Osborne J, Jacobs MF, Clines GT, Miller BS, Hughes DT et al (2020) Outcome of clinical genetic testing in patients with features suggestive for hereditary predisposition to PTH-mediated hypercalcemia. Horm Cancer 11(5\u20136):250\u2013255","journal-title":"Horm Cancer"},{"issue":"4","key":"2366_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jc.2010-1338","volume":"96","author":"J Costa-Guda","year":"2011","unstructured":"Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A (2011) Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J Clin Endocrinol Metab 96(4):1\u20136","journal-title":"J Clin Endocrinol Metab"},{"key":"2366_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/510985","volume":"2015","author":"MS Elston","year":"2015","unstructured":"Elston MS, Meyer-Rochow GY, Dray M, Swarbrick M, Conaglen JV (2015) Early onset primary hyperparathyroidism associated with a novel germline mutation in CDKN1B. Case Rep Endocrinol 2015:1\u20134","journal-title":"Case Rep Endocrinol"},{"key":"2366_CR79","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s12020-016-0941-6","volume":"55","author":"S Borsari","year":"2016","unstructured":"Borsari S, Pardi E, Pellegata NS, Lee M, Saponaro F, Torregrossa L et al (2016) Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. Endocrine 55:386\u2013397","journal-title":"Endocrine"},{"key":"2366_CR80","doi-asserted-by":"crossref","unstructured":"Cusan M, Mungo G, Zompit MDM, Segatto I, Belletti B, Baldassarre G (2018) Landscape of CDKN1B mutations in luminal breast cancer and other hormone-driven human tumors. Front Endocrinol (Lausanne) 9(Jul):1\u201310","DOI":"10.3389\/fendo.2018.00393"},{"issue":"9","key":"2366_CR81","first-page":"781","volume":"36","author":"M Lee","year":"2013","unstructured":"Lee M, Pellegata NS (2013) Multiple endocrine neoplasia syndromes associated with mutation of p27. J Endocrinol Invest 36(9):781\u2013787","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2366_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EC-14-0116","volume":"4","author":"E Pardi","year":"2015","unstructured":"Pardi E, Mariotti S, Pellegata NS, Benfini K, Borsari S, Saponaro F et al (2015) Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4. Endocr Connect 4(1):1\u20138","journal-title":"Endocr Connect"},{"issue":"March","key":"2366_CR83","first-page":"1","volume":"13","author":"E Lavezzi","year":"2022","unstructured":"Lavezzi E, Brunetti A, Smiroldo V, Nappo G, Pedicini V, Vitali E et al (2022) Case report: new CDKN1B mutation in multiple endocrine neoplasia type 4 and brief literature review on clinical management. Front Endocrinol (Lausanne) 13(March):1\u20137","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2366_CR84","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1210\/jc.2019-00082","volume":"104","author":"A Frederiksen","year":"2019","unstructured":"Frederiksen A, Rossing M, Hermann P, Ejersted C, Thakker RV (2019) Clinical features of multiple endocrine neoplasia type 4\u2014novel pathogenic variant and review of published cases. J Clin Endocrinol Metab 104:3637\u20133646","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2366_CR85","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12020-015-0540-y","volume":"49","author":"S Sambugaro","year":"2015","unstructured":"Sambugaro S, Di Ruvo M, Ambrosio MR, Pellegata NS, Bellio M, Guerra A et al (2015) Early onset acromegaly associated with a novel deletion in CDKN1B 5\u2032UTR region. Endocrine 49(1):58\u201364","journal-title":"Endocrine"},{"issue":"11","key":"2366_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/humu.21354","volume":"31","author":"S Molatore","year":"2010","unstructured":"Molatore S, Marinoni I, Lee M, Pulz E, Ambrosio MR, Uberti EC et al (2010) A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat 31(11):1\u201311","journal-title":"Hum Mutat"},{"issue":"10","key":"2366_CR87","doi-asserted-by":"publisher","first-page":"T195","DOI":"10.1530\/ERC-17-0243","volume":"24","author":"R Alrezk","year":"2017","unstructured":"Alrezk R, Hannah-Shmouni F, Stratakis CA (2017) MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer 24(10):T195-208","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2366_CR88","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s12020-016-0941-6","volume":"55","author":"S Borsari","year":"2017","unstructured":"Borsari S, Pardi E, Pellegata NS, Lee M, Saponaro F, Torregrossa L et al (2017) Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. Endocrine 55(2):386\u2013397","journal-title":"Endocrine"},{"issue":"3","key":"2366_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003350","volume":"9","author":"G Occhi","year":"2013","unstructured":"Occhi G, Regazzo D, Trivellin G, Boaretto F, Ciato D, Bobisse S et al (2013) A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet 9(3):e1003350","journal-title":"PLoS Genet"},{"issue":"2","key":"2366_CR90","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10689-019-00152-6","volume":"19","author":"P Brock","year":"2020","unstructured":"Brock P, Bustamante Alvarez J, Mortazavi A, Roychowdhury S, Phay J, Khawaja RA et al (2020) Co-occurrence of multiple endocrine neoplasia type 4 and spinal neurofibromatosis: a case report. Fam Cancer 19(2):189\u2013192","journal-title":"Fam Cancer"},{"key":"2366_CR91","doi-asserted-by":"publisher","first-page":"bcr2015213934","DOI":"10.1136\/bcr-2015-213934","volume":"2016","author":"MJ Bugalho","year":"2016","unstructured":"Bugalho MJ, Domingues R (2016) Uncommon association of cerebral meningioma, parathyroid adenoma and papillary thyroid carcinoma in a patient harbouring a rare germline variant in the CDKN1B gene. BMJ Case Rep 2016:bcr2015213934","journal-title":"BMJ Case Rep"},{"issue":"8","key":"2366_CR92","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1210\/jc.2006-2843","volume":"92","author":"M Georgitsi","year":"2007","unstructured":"Georgitsi M, Raitila A, Karhu A, Van Der Luijt RB, Aalfs CM, Sane T et al (2007) Germline CDKN1B\/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 92(8):3321\u20133325","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2366_CR93","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1530\/EJE-11-0929","volume":"166","author":"D Malanga","year":"2012","unstructured":"Malanga D, De Gisi S, Riccardi M, Scrima M, De Marco C, Robledo M et al (2012) Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. Eur J Endocrinol 166(3):551\u2013560","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2366_CR94","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","volume":"2","author":"H Donis-keller","year":"1993","unstructured":"Donis-keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al (1993) Mutations in the RET proto-oncogene are associated with MEN 2a and FMTC. Hum Mol Genet 2(7):851\u2013856","journal-title":"Hum Mol Genet"},{"issue":"79","key":"2366_CR95","first-page":"163","volume":"2022","author":"JS Mathiesen","year":"2020","unstructured":"Mathiesen JS, Effraimidis G, Rossing M, Rasmussen \u00c5K, Hoejberg L, Bastholt L et al (2020) Multiple endocrine neoplasia type 2: a review. Semin Cancer Biol 2022(79):163\u2013179","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"2366_CR96","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s002689900123","volume":"20","author":"JL Kraimps","year":"1996","unstructured":"Kraimps JL, Denizot A, Carnaille B, Henry JF, Proye C, Bacourt F et al (1996) Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. World J Surg 20(7):808\u2013813","journal-title":"World J Surg"},{"issue":"7","key":"2366_CR97","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3390\/cancers15072125","volume":"15","author":"M Holm","year":"2023","unstructured":"Holm M, Vestergaard P, Poulsen MM, Rasmussen \u00c5K, Feldt-Rasmussen U, Bay M et al (2023) Primary hyperparathyroidism in multiple endocrine neoplasia type 2A in Denmark: a nationwide population-based retrospective study in Denmark 1930\u20132021. Cancers (Basel) 15(7):2125","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2366_CR98","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells","year":"2015","unstructured":"Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567\u2013610","journal-title":"Thyroid"},{"issue":"4","key":"2366_CR99","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2796.1995.tb01212.x","volume":"238","author":"E Raue","year":"1995","unstructured":"Raue E, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A et al (1995) Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238(4):369\u2013373","journal-title":"J Intern Med"},{"issue":"6","key":"2366_CR100","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1530\/EC-20-0163","volume":"9","author":"LV Larsen","year":"2020","unstructured":"Larsen LV, Mirebeau-Prunier D, Imai T, Alvarez-Escola C, Hasse-Lazar K, Censi S et al (2020) Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. Endocr Connect 9(6):489\u2013497","journal-title":"Endocr Connect"},{"issue":"9","key":"2366_CR101","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1007\/s40618-023-02032-4","volume":"46","author":"AA Figueiredo","year":"2023","unstructured":"Figueiredo AA, Saramago A, Cavaco BM, Sim\u00f5es-Pereira J, Leite V (2023) Familial parathyroid tumours\u2014comparison of clinical profiles between syndromes. J Endocrinol Invest 46(9):1799\u20131806","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2366_CR102","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/humu.21385","volume":"32","author":"K Frank-Raue","year":"2011","unstructured":"Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I et al (2011) Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat 32(1):51\u201358","journal-title":"Hum Mutat"},{"issue":"2","key":"2366_CR103","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12020-020-02232-5","volume":"68","author":"A Machens","year":"2020","unstructured":"Machens A, Elwerr M, Lorenz K, Weber F, Dralle H (2020) 100-Year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A. Endocrine 68(2):368\u2013376","journal-title":"Endocrine"},{"issue":"6","key":"2366_CR104","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0039-6060(96)80042-0","volume":"120","author":"KKF Herfarth","year":"1996","unstructured":"Herfarth KKF, Bartsch D, Doherty GM, Wells J, Lairmore TC, Kraimps JL et al (1996) Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 120(6):966\u2013974","journal-title":"Surgery"},{"issue":"7","key":"2366_CR105","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ng.861","volume":"43","author":"I Comino-M\u00e9ndez","year":"2011","unstructured":"Comino-M\u00e9ndez I, Gracia-Azn\u00e1rez FJ, Schiavi F, Landa I, Leandro-Garc\u00eda LJ, Let\u00f3n R et al (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43(7):663\u2013667","journal-title":"Nat Genet"},{"issue":"10","key":"2366_CR106","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","volume":"18","author":"N Burnichon","year":"2012","unstructured":"Burnichon N, Casco\u0144 A, Schiavi F, Morales NP, Comino-M\u00e9ndez I, Abermil N et al (2012) MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 18(10):2828\u20132837","journal-title":"Clin Cancer Res"},{"key":"2366_CR107","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12022-022-09705-5","volume":"33","author":"V Nos\u00e9","year":"2022","unstructured":"Nos\u00e9 V, Gill A, Teijeiro JMC, Perren A, Erickson L (2022) Overview of the 2022 WHO classification of familial endocrine tumor syndromes. Endocr Pathol 33:197\u2013227","journal-title":"Endocr Pathol"},{"issue":"11","key":"2366_CR108","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1210\/js.2017-00135","volume":"1","author":"KL Roszko","year":"2017","unstructured":"Roszko KL, Blouch E, Blake M, Powers JF, Tischler AS, Hodin R et al (2017) Case report of a prolactinoma in a patient with a novel MAX mutation and bilateral pheochromocytomas. J Endocr Soc 1(11):1401\u20131407","journal-title":"J Endocr Soc"},{"issue":"2","key":"2366_CR109","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1210\/jc.2015-2592","volume":"101","author":"E Korpershoek","year":"2016","unstructured":"Korpershoek E, Koffy D, Eussen BH, Oudijk L, Papathomas TG, Van Nederveen FH et al (2016) Complex MAX rearrangement in a family with malignant pheochromocytoma, renal oncocytoma, and erythrocytosis. J Clin Endocrinol Metab 101(2):453\u2013460","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2366_CR110","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1055\/a-1186-0790","volume":"52","author":"S Petignot","year":"2020","unstructured":"Petignot S, Daly AF, Castermans E, Korpershoek E, Scagnol I, Beckers P et al (2020) Pancreatic neuroendocrine neoplasm associated with a familial MAX deletion. Horm Metab Res 52(11):784\u2013787","journal-title":"Horm Metab Res"},{"issue":"12","key":"2366_CR111","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1210\/clinem\/dgad368","volume":"108","author":"R Tora","year":"2023","unstructured":"Tora R, Welch J, Sun J, Agarwal SK, Bell DA, Merino M et al (2023) Phenotypic profiling and molecular mechanisms in hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 108(12):3165\u20133177","journal-title":"J Clin Endocrinol Metab"},{"key":"2366_CR112","doi-asserted-by":"publisher","first-page":"1761030","DOI":"10.1155\/2019\/1761030","volume":"2019","author":"F Torresan","year":"2019","unstructured":"Torresan F, Iacobone M (2019) Clinical features, treatment, and surveillance of hyperparathyroidism-jaw tumor syndrome: an up-to-date and review of the literature. Int J Endocrinol 2019:1761030","journal-title":"Int J Endocrinol"},{"key":"2366_CR113","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejrad.2017.07.026","volume":"95","author":"I Christakis","year":"2017","unstructured":"Christakis I, Vu T, Chuang HH, Fellman B, Silva-Figueroa AM, Williams MD et al (2017) The diagnostic accuracy of neck ultrasound, 4D-computed tomographyand sestamibi imaging in parathyroid carcinoma. Eur J Radiol 95:82\u201388","journal-title":"Eur J Radiol"},{"issue":"2","key":"2366_CR114","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s00268-019-05156-y","volume":"44","author":"M Iacobone","year":"2020","unstructured":"Iacobone M, Camozzi V, Mian C, Pennelli G, Pagetta C, Casal Ide E et al (2020) Long-term outcomes of parathyroidectomy in hyperparathyroidism-jaw tumor syndrome: analysis of five families with CDC73 mutations. World J Surg 44(2):508\u2013516","journal-title":"World J Surg"},{"issue":"6","key":"2366_CR115","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.surg.2014.08.004","volume":"156","author":"A Mehta","year":"2015","unstructured":"Mehta A, Patel D, Rosenberg A, Boufraqech M, Ellis R, Nilubol N et al (2015) Hyperparathyroidism-jaw tumor syndrome: results of surgical management. Surgery 156(6):1315\u20131325","journal-title":"Surgery"},{"issue":"5","key":"2366_CR116","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.surg.2007.12.012","volume":"143","author":"MS Sarquis","year":"2008","unstructured":"Sarquis MS, Silveira LG, Pimenta FJ, Dias EP, Teh BT, Friedman E et al (2008) Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 143(5):630\u2013640","journal-title":"Surgery"},{"issue":"7","key":"2366_CR117","doi-asserted-by":"publisher","first-page":"R441","DOI":"10.1530\/ERC-19-0135","volume":"26","author":"F Cetani","year":"2019","unstructured":"Cetani F, Marcocci C, Torregrossa L, Pardi E (2019) Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer 26(7):R441\u2013R464","journal-title":"Endocr Relat Cancer"},{"key":"2366_CR118","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/BF03346439","volume":"31","author":"F Cetani","year":"2008","unstructured":"Cetani F, Pardi E, Ambrogini E, Banti C, Viacava P, Borsari S et al (2008) Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment. J Endocrinol Invest 31:900\u2013904","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"2366_CR119","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1210\/jc.2005-1239","volume":"91","author":"V Guarnieri","year":"2006","unstructured":"Guarnieri V, Scillitani A, Muscarella LA, Battista C, Bonfitto N, Bisceglia M et al (2006) Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab 91(8):2827\u20132832","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2366_CR120","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.tripleo.2005.06.011","volume":"101","author":"MJ Aldred","year":"2006","unstructured":"Aldred MJ, Talacko AA, Savarirayan R, Murdolo V, Mills AE, Radden BG et al (2006) Dental findings in a family with hyperparathyroidism-jaw tumor syndrome and a novel HRPT2 gene mutation. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 101(2):212\u2013218","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol"},{"issue":"4","key":"2366_CR121","first-page":"1449","volume":"85","author":"CJ Haven","year":"2000","unstructured":"Haven CJ, Wong FK, Van Dam EWCM, Van Der Luijt R, Van Asperen C, Jansen J et al (2000) A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 85(4):1449\u20131454","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2366_CR122","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2796.2004.01421.x","volume":"257","author":"KJ Bradley","year":"2005","unstructured":"Bradley KJ, Hobbs MR, Buley ID, Carpten JD, Cavaco BM, Fares JE et al (2005) Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med 257(1):18\u201326","journal-title":"J Intern Med"},{"issue":"5","key":"2366_CR123","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00423-009-0511-y","volume":"394","author":"M Iacobone","year":"2009","unstructured":"Iacobone M, Masi G, Barzon L, Porzionato A, MacChi V, Ciarleglio FA et al (2009) Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred. Langenbecks Arch Surg 394(5):817\u2013825","journal-title":"Langenbecks Arch Surg"},{"issue":"4","key":"2366_CR124","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ng1048","volume":"32","author":"JD Carpten","year":"2002","unstructured":"Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilsons J et al (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32(4):676\u2013680","journal-title":"Nat Genet"},{"issue":"3","key":"2366_CR125","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/humu.21188","volume":"31","author":"PJ Newey","year":"2010","unstructured":"Newey PJ, Bowl MR, Cranston T, Thakker RV (2010) Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat 31(3):295\u2013307","journal-title":"Hum Mutat"},{"issue":"12","key":"2366_CR126","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/humu.23337","volume":"38","author":"L Cardoso","year":"2017","unstructured":"Cardoso L, Stevenson M, Thakker RV (2017) Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. Hum Mutat 38(12):1621\u20131648","journal-title":"Hum Mutat"},{"issue":"2","key":"2366_CR127","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1210\/jc.2012-2789","volume":"98","author":"L Bricaire","year":"2013","unstructured":"Bricaire L, Odou MF, Cardot-Bauters C, Delemer B, North MO, Salenave S et al (2013) Frequent large germline HRPT2 deletions in a french national cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab 98(2):403\u2013408","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2366_CR128","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1530\/EC-13-0046","volume":"2","author":"F Cetani","year":"2013","unstructured":"Cetani F, Banti C, Pardi E, Borsari S, Viacava P, Miccoli P et al (2013) CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocr Connect 2(4):186\u2013195","journal-title":"Endocr Connect"},{"key":"2366_CR129","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1056\/NEJMoa031237","volume":"349","author":"TM Shattuck","year":"2003","unstructured":"Shattuck TM, V\u00e4lim\u00e4ki S, Obara T, Gaz RD, Clark OH, Shoback D et al (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722\u20131729","journal-title":"N Engl J Med"},{"issue":"11","key":"2366_CR130","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1210\/jc.2004-0294","volume":"89","author":"F Cetani","year":"2004","unstructured":"Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L et al (2004) Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 89(11):5583\u20135591","journal-title":"J Clin Endocrinol Metab"},{"key":"2366_CR131","doi-asserted-by":"crossref","unstructured":"Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN et al (2002) Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 81(1):1\u201326. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11807402.","DOI":"10.1097\/00005792-200201000-00001"},{"issue":"4","key":"2366_CR132","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00774-013-0551-9","volume":"32","author":"N Pontikides","year":"2014","unstructured":"Pontikides N, Karras S, Kaprara A, Anagnostis P, Mintziori G, Goulis DG et al (2014) Genetic basis of familial isolated hyperparathyroidism: a case series and a narrative review of the literature. J Bone Miner Metab 32(4):351\u2013366","journal-title":"J Bone Miner Metab"},{"issue":"9","key":"2366_CR133","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1210\/jc.2018-02789\/5371251","volume":"104","author":"SJ Marx","year":"2019","unstructured":"Marx SJ (2019) New concepts about familial isolated hyperparathyroidism. J Clin Endocrinol Metab 104(9):4058\u20134066. https:\/\/doi.org\/10.1210\/jc.2018-02789\/5371251","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2366_CR134","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1210\/jc.2003-030675","volume":"89","author":"WF Simonds","year":"2004","unstructured":"Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ (2004) Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 89(1):96\u2013102","journal-title":"J Clin Endocrinol Metab"},{"key":"2366_CR135","doi-asserted-by":"crossref","unstructured":"Warner J, Epstein M, Sweet A, Singh D, Burgess J, Stranks S et al (2004) Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet 41(3):155\u2013160. http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14985373","DOI":"10.1136\/jmg.2003.016725"},{"issue":"2","key":"2366_CR136","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2265.2006.02438.x","volume":"64","author":"F Cetani","year":"2006","unstructured":"Cetani F, Pardi E, Ambrogini E, Lemmi M, Borsari S, Cianferotti L et al (2006) Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol (Oxf) 64(2):146\u2013152","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2366_CR137","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1210\/jc.2017-01249","volume":"102","author":"K Van Der Tuin","year":"2017","unstructured":"Van Der Tuin K, Tops CMJ, Adank MA, Cobben JM, Hamdy NAT, Jongmans MC et al (2017) CDC73-related disorders: clinical manifestations and case detection in primary hyperparathyroidism. J Clin Endocrinol Metab 102(12):4534\u20134540","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2366_CR138","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ajhg.2016.08.018","volume":"99","author":"B Guan","year":"2016","unstructured":"Guan B, Welch JM, Sapp JC, Ling H, Li Y, Johnston JJ et al (2016) GCM2-activating mutations in familial isolated hyperparathyroidism. Am J Hum Genet 99(5):1034\u20131044","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2366_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0210662","volume":"14","author":"T Yamada","year":"2019","unstructured":"Yamada T, Tatsumi N, Anraku A, Suzuki H, Kamejima S, Uchiyama T et al (2019) Gcm2 regulates the maintenance of parathyroid cells in adult mice. PLoS ONE 14(1):1\u201315","journal-title":"PLoS ONE"},{"issue":"3","key":"2366_CR140","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1530\/EJE-21-0433","volume":"186","author":"L Canaff","year":"2022","unstructured":"Canaff L, Guarnieri V, Kim Y, Wong BYL, Nolin-Lapalme A, Cole DEC et al (2022) Novel Glial Cells Missing-2 (GCM2) variants in parathyroid disorders. Eur J Endocrinol 186(3):351\u2013366","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2366_CR141","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1210\/js.2017-00043","volume":"1","author":"B Guan","year":"2017","unstructured":"Guan B, Welch JM, Vemulapalli M, Li Y, Ling H, Kebebew E et al (2017) Ethnicity of patients with germline GCM2-activating variants and primary hyperparathyroidism. J Endocr Soc 1(5):488\u2013499","journal-title":"J Endocr Soc"},{"key":"2366_CR142","doi-asserted-by":"crossref","unstructured":"Szalat A, Shpitzen S, Pollack R, Mazeh H, Durst R, Meiner V (2023) GCM2 p.Tyr394Ser variant in Ashkenazi Israeli patients with suspected familial isolated hyperparathyroidism. Front Endocrinol (Lausanne) 14:1254156","DOI":"10.3389\/fendo.2023.1254156"},{"issue":"7","key":"2366_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jendso\/bvad086","volume":"7","author":"L Tolkin","year":"2023","unstructured":"Tolkin L, Klein V, Frankel M, Altarescu G, Beeri R, Munter G (2023) Variant Tyr 394Ser in the GCM2 gene is rare in a cohort of Ashkenazi Jews with primary hyperparathyroidism. J Endocr Soc 7(7):1\u20134. https:\/\/doi.org\/10.1210\/jendso\/bvad086","journal-title":"J Endocr Soc"},{"issue":"2","key":"2366_CR144","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40618-019-01107-5","volume":"43","author":"F Cetani","year":"2020","unstructured":"Cetani F, Pardi E, Aretini P, Saponaro F, Borsari S, Mazoni L et al (2020) Whole exome sequencing in familial isolated primary hyperparathyroidism. J Endocrinol Invest 43(2):231\u2013245","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2366_CR145","doi-asserted-by":"publisher","first-page":"E2021","DOI":"10.1210\/clinem\/dgab929","volume":"107","author":"S Vincze","year":"2022","unstructured":"Vincze S, Peters NV, Kuo CL, Brown TC, Korah R, Murtha TD et al (2022) GCM2 variants in familial and multiglandular primary hyperparathyroidism. J Clin Endocrinol Metab 107(5):E2021\u2013E2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2366_CR146","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jamcollsurg.2018.01.007","volume":"226","author":"M El Lakis","year":"2018","unstructured":"El Lakis M, Nockel P, Gaitanidis A, Guan B, Agarwal S, Welch J et al (2018) Probability of positive genetic testing results in patients with family history of primary hyperparathyroidism. J Am Coll Surg 226(5):933\u2013938","journal-title":"J Am Coll Surg"},{"issue":"5","key":"2366_CR147","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ajhg.2016.08.018","volume":"99","author":"B Guan","year":"2016","unstructured":"Guan B, Welch JM, Sapp JC, Ling H, Li Y, Johnston JJ et al (2016) GCM2-activating mutations in familial isolated hyperparathyroidism. Am J Hum Genet 99(5):1034\u20131044. https:\/\/doi.org\/10.1016\/j.ajhg.2016.08.018","journal-title":"Am J Hum Genet"},{"key":"2366_CR148","doi-asserted-by":"publisher","unstructured":"Parekh VI, Brinster LR, Guan B, Simonds WF, Weinstein LS, Agarwal SK (2023) A knock-in mouse model of the Gcm2 variant p.Y392S develops normal parathyroid glands. J Endocr Soc 7(11):1\u20139. https:\/\/doi.org\/10.1210\/jendso\/bvad126","DOI":"10.1210\/jendso\/bvad126"},{"issue":"1","key":"2366_CR149","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.surg.2017.04.027","volume":"163","author":"LM El","year":"2018","unstructured":"El LM, Nockel P, Guan B, Agarwal S, Welch J, Simonds WF et al (2018) Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure. Surgery 163(1):31\u201334. https:\/\/doi.org\/10.1016\/j.surg.2017.04.027","journal-title":"Surgery"},{"issue":"4","key":"2366_CR150","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s002230001201","volume":"68","author":"J Hinnie","year":"2001","unstructured":"Hinnie J, Bell E, McKillop E, Gallacher S (2001) The prevalence of familial hypocalciuric hypercalcemia. Calcif Tissue Int 68(4):216\u2013218","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2366_CR151","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1172\/JCI17416","volume":"111","author":"CH Kos","year":"2003","unstructured":"Kos CH, Karaplis AC, Bin PJ, Hediger MA, Goltzman D, Mohammad KS et al (2003) The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest 111(7):1021\u20131028","journal-title":"J Clin Invest"},{"issue":"2","key":"2366_CR152","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1530\/EJE-21-1044","volume":"186","author":"J Bollerslev","year":"2022","unstructured":"Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L et al (2022) European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). Eur J Endocrinol 186(2):R33-63","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2366_CR153","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13402-012-0100-x","volume":"35","author":"V Guarnieri","year":"2012","unstructured":"Guarnieri V, Battista C, Muscarella LA, Bisceglia M, De Martino D, Baorda F et al (2012) CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cell Oncol 35(6):411\u2013422","journal-title":"Cell Oncol"},{"issue":"12","key":"2366_CR154","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/hmg\/dds105","volume":"21","author":"FM Hannan","year":"2012","unstructured":"Hannan FM, Nesbit MA, Zhang C, Cranston T, Curley AJ, Harding B et al (2012) Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Genet 21(12):2768\u20132778","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2366_CR155","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/cen.14211","volume":"93","author":"C Mouly","year":"2020","unstructured":"Mouly C, Vargas-Poussou R, Lienhardt A, Silve C, Hureaux M, Magdelaine C et al (2020) Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: a multicentre study of 77 adult patients. Clin Endocrinol (Oxf) 93(3):248\u2013260","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2366_CR156","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1210\/jc.2015-3442","volume":"101","author":"R Vargas-Poussou","year":"2016","unstructured":"Vargas-Poussou R, Mansour-Hendili L, Baron S, Bertocchio JP, Travers C, Simian C et al (2016) Familial hypocalciuric hypercalcemia types 1 and 3 and primary hyperparathyroidism\u202f: similarities and differences. J Clin Endocrinol Metab 101(5):2185\u20132195","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2366_CR157","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1210\/jcem-72-3-541","volume":"72","author":"AF Firek","year":"1991","unstructured":"Firek AF, Kao PC, Heath H (1991) Plasma intact parathyroid hormone (PTH) and PTH-related peptide in familial benign hypercalcemia: greater responsiveness to endogenous PTH than in primary hyperparathyroidism. J Clin Endocrinol Metab 72(3):541\u2013546","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"2366_CR158","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJM198010023031409","volume":"303","author":"S Marx","year":"1980","unstructured":"Marx S (1980) Familial hypocalciuric hypercalcemia. N Engl J Med 303(14):810\u2013811","journal-title":"N Engl J Med"},{"issue":"6","key":"2366_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbm4.10362","volume":"4","author":"AR Jones","year":"2020","unstructured":"Jones AR, Hare MJL, Brown J, Yang J, Meyer C, Milat F et al (2020) Familial hypocalciuric hypercalcemia in pregnancy: diagnostic pitfalls. JBMR Plus 4(6):1\u20135","journal-title":"JBMR Plus"},{"issue":"6","key":"2366_CR160","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.ajhg.2020.04.006","volume":"106","author":"R Dershem","year":"2020","unstructured":"Dershem R, Gorvin CM, Metpally RPR, Krishnamurthy S, Smelser DT, Hannan FM et al (2020) Familial hypocalciuric hypercalcemia type 1 and autosomal-dominant hypocalcemia type 1: prevalence in a large healthcare population. Am J Hum Genet 106(6):734\u2013747","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2366_CR161","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41574-018-0115-0","volume":"15","author":"FM Hannan","year":"2018","unstructured":"Hannan FM, Kallay E, Chang W, Brandi ML, Thakker RV (2018) Calcium-sensing receptor in physiology and in calcitropic and non-calcitropic diseases. Nat Rev Endocrinol 15(1):33\u201351","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2366_CR162","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa040008","volume":"351","author":"JC Pallais","year":"2004","unstructured":"Pallais JC, Kifor O, Chen YB, Slovik D, Brown EM (2004) Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N Engl J Med 351(4):362\u2013369","journal-title":"N Engl J Med"},{"issue":"1","key":"2366_CR163","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/EJE-17-0172","volume":"177","author":"L Song","year":"2017","unstructured":"Song L, Liu L, Miller RT, Yan SX, Jackson N, Holt SA et al (2017) Glucocorticoid-responsive lymphocytic parathyroiditis and hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor: a case report and literature review. Eur J Endocrinol 177(1):K1-6","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2366_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.126449","volume":"4","author":"N Makita","year":"2019","unstructured":"Makita N, Ando T, Sato J, Manaka K, Mitani K, Kikuchi Y et al (2019) Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody. JCI Insight 4(8):1\u201313","journal-title":"JCI Insight"},{"issue":"20","key":"2366_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.156742","volume":"7","author":"N Makita","year":"2022","unstructured":"Makita N, Sato J, Manaka K, Akahane K, Ito T, Yamazaki H et al (2022) Successful prednisolone or calcimimetic treatment of acquired hypocalciuric hypercalcemia caused by biased allosteric CaSR autoantibodies. JCI Insight 7(20):1\u201315","journal-title":"JCI Insight"},{"issue":"6","key":"2366_CR166","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/jbmr.2778","volume":"31","author":"CM Gorvin","year":"2016","unstructured":"Gorvin CM, Cranston T, Hannan FM, Rust N, Qureshi A, Nesbit MA et al (2016) A G-protein subunit-\u03b111 loss-of-function mutation, Thr54Met, causes familial hypocalciuric hypercalcemia type 2 (FHH2). J Bone Miner Res 31(6):1200\u20131206","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2366_CR167","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/jbmr.3241","volume":"33","author":"CM Gorvin","year":"2018","unstructured":"Gorvin CM, Hannan FM, Cranston T, Valta H, Makitie O, Schalin-Jantti C et al (2018) Cinacalcet rectifies hypercalcemia in a patient with familial hypocalciuric hypercalcemia type 2 (FHH2) caused by a germline loss-of-function G\u03b111 mutation. J Bone Miner Res 33(1):32\u201341","journal-title":"J Bone Miner Res"},{"issue":"18","key":"2366_CR168","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1093\/hmg\/ddv226","volume":"24","author":"FM Hannan","year":"2015","unstructured":"Hannan FM, Howles SA, Rogers A, Cranston T, Gorvin CM, Babinsky VN et al (2015) Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype-phenotype correlations, codon bias and dominant-negative effects. Hum Mol Genet 24(18):5079\u20135092","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2366_CR169","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0002-9343(92)90229-5","volume":"93","author":"CT McMurtry","year":"1992","unstructured":"McMurtry CT, Schranck FW, Walkenhorst DA, Murphy WA, Kocher DB, Teitelbaum SL et al (1992) Significant developmental elevation in serum parathyroid hormone levels in a large kindred with familial benign (hypocalciuric) hypercalcemia. Am J Med 93(3):247\u2013258","journal-title":"Am J Med"},{"issue":"14","key":"2366_CR170","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMc1511646","volume":"374","author":"SA Howles","year":"2016","unstructured":"Howles SA, Hannan FM, Babinsky VN, Rogers A, Gorvin CM, Rust N et al (2016) Cinacalcet for symptomatic hypercalcemia caused by AP2S1 mutations. N Engl J Med 374(14):1396\u20131398","journal-title":"N Engl J Med"},{"issue":"12","key":"2366_CR171","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1210\/jc.2013-2571","volume":"98","author":"Y Fujisawa","year":"2013","unstructured":"Fujisawa Y, Yamaguchi R, Satake E, Ohtaka K, Nakanishi T, Ozono K et al (2013) Identification of AP2S1 mutation and effects of low calcium formula in an infant with hypercalcemia and hypercalciuria. J Clin Endocrinol Metab 98(12):2022\u20132027","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2366_CR172","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1210\/jc.2014-1120","volume":"99","author":"GN Hendy","year":"2014","unstructured":"Hendy GN, Canaff L, Newfield RS, Tripto-Shkolnik L, Wong BYL, Lee BSP et al (2014) Codon Arg15 mutations of the AP2S1 gene: common occurrence in familial hypocalciuric hypercalcemia cases negative for calcium-sensing receptor (CASR) mutations. J Clin Endocrinol Metab 99(7):1311\u20131315","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2366_CR173","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1530\/EJE-16-0842","volume":"176","author":"S Hovden","year":"2017","unstructured":"Hovden S, Rejnmark L, Ladefoged SA, Nissen PH (2017) AP2S1 and GNA11 mutations\u2014not a common cause of familial hypocalciuric hypercalcemia. Eur J Endocrinol 176(2):177\u2013185","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2366_CR174","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/hmg\/ddy010","volume":"27","author":"CM Gorvin","year":"2018","unstructured":"Gorvin CM, Metpally R, Stokes VJ, Hannan FM, Krishnamurthy SB, Overton JD et al (2018) Large-scale exome datasets reveal a new class of adaptor-related protein complex 2 sigma subunit (AP2\u03c3) mutations, located at the interface with the AP2 alpha subunit, that impair calcium-sensing receptor signalling. Hum Mol Genet 27(5):901\u2013911","journal-title":"Hum Mol Genet"},{"issue":"10","key":"2366_CR175","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/hmg\/ddab076","volume":"30","author":"FM Hannan","year":"2021","unstructured":"Hannan FM, Stevenson M, Bayliss AL, Stokes VJ, Stewart M, Kooblall KG et al (2021) Ap2s1 mutation causes hypercalcaemia in mice and impairs interaction between calcium-sensing receptor and adaptor protein-2. Hum Mol Genet 30(10):880\u2013892","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2366_CR176","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1210\/clinem\/dgz233","volume":"105","author":"SJ Marx","year":"2020","unstructured":"Marx SJ, Sinaii N (2020) Neonatal severe hyperparathyroidism: novel insights from calcium, PTH, and the CASR gene. J Clin Endocrinol Metab 105(4):1061\u20131078","journal-title":"J Clin Endocrinol Metab"},{"key":"2366_CR177","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1172\/JCI117062","volume":"93","author":"M Pollak","year":"1994","unstructured":"Pollak M, Chou YHW, Marx S, Steinmann B, Cole D, Brandi M et al (1994) Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. J Clin Invest 93:1108\u20131112","journal-title":"J Clin Invest"},{"issue":"4","key":"2366_CR178","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jpedsurg.2009.08.005","volume":"45","author":"S Al-Shanafey","year":"2010","unstructured":"Al-Shanafey S, Al-Hosaini R, Al-Ashwal A, Al-Rabeeah A (2010) Surgical management of severe neonatal hyperparathyroidism: one center\u2019s experience. J Pediatr Surg 45(4):714\u2013717","journal-title":"J Pediatr Surg"},{"issue":"3","key":"2366_CR179","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1530\/JME-16-0124","volume":"57","author":"FM Hannan","year":"2016","unstructured":"Hannan FM, Babinsky VN, Thakker RV (2016) Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis. J Mol Endocrinol 57(3):R127\u2013R142","journal-title":"J Mol Endocrinol"},{"key":"2366_CR180","first-page":"150040","volume":"2015","author":"MM Fisher","year":"2015","unstructured":"Fisher MM, Cabrera SM, Imel EA (2015) Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients. Endocrinol Diabetes Metab Case Rep 2015:150040","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"10","key":"2366_CR181","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00431-004-1491-0","volume":"163","author":"S Waller","year":"2004","unstructured":"Waller S, Kurzawinski T, Spitz L, Thakker R, Cranston T, Pearce S et al (2004) Neonatal severe hyperparathyroidism: genotype\/phenotype correlation and the use of pamidronate as rescue therapy. Eur J Pediatr 163(10):589\u2013594","journal-title":"Eur J Pediatr"},{"issue":"3","key":"2366_CR182","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1542\/peds.2011-0128","volume":"129","author":"A Wilhelm-Bals","year":"2012","unstructured":"Wilhelm-Bals A, Parvex P, Magdelaine C, Girardin E (2012) Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism. Pediatrics 129(3):812\u2013816","journal-title":"Pediatrics"},{"issue":"10","key":"2366_CR183","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1359\/jbmr.060702","volume":"21","author":"TG Kelly","year":"2006","unstructured":"Kelly TG, Shattuck TM, Reyes-Mugica M, Stewart AF, Simonds WF, Udelsman R et al (2006) Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res 21(10):1666\u20131671","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02366-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02366-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02366-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T04:32:43Z","timestamp":1725251563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02366-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":183,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["2366"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02366-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"25 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The first and Corresponding Author of this paper is an Associate Editor of JENI. All other authors declare that they have no conflicts of interest regarding material presented in this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No approval needed for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors received the permission from five patients followed-up in the outpatient clinic for anonymous use of their CT, MRI and PET scans for research purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The present Review study did not involve research on human participants and\/or animals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}